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Background-—We sought to characterize growth between birth and age 3 years in infants with hypoplastic left heart syndrome
who underwent the Norwood procedure.
Methods and Results-—We performed a secondary analysis using the Single Ventricle Reconstruction Trial database after
excluding patients <37 weeks gestation (N=498). We determined length-for-age z score (LAZ) and weight-for-age z score (WAZ) at
birth and age 3 years and change in WAZ over 4 clinically relevant time periods. We identiﬁed correlates of change in WAZ and LAZ
using multivariable linear regression with bootstrapping. Mean WAZ and LAZ were below average relative to the general population
at birth (P<0.001, P=0.05, respectively) and age 3 years (P<0.001 each). The largest decrease in WAZ occurred between birth and
Norwood discharge; the greatest gain occurred between stage II and 14 months. At age 3 years, WAZ and LAZ were <2 in 6% and
18%, respectively. Factors associated with change in WAZ differed among time periods. Shunt type was associated with change in
WAZ only in the Norwood discharge to stage II period; subjects with a Blalock-Taussig shunt had a greater decline in WAZ than
those with a right ventricle-pulmonary artery shunt (P=0.002).
Conclusions-—WAZ changed over time and the predictors of change in WAZ varied among time periods. By age 3 years, subjects
remained small and three times as many children were short as were underweight (>2 SD below normal). Failure to ﬁnd consistent
risk factors supports the strategy of tailoring nutritional therapies to patient- and stage-speciﬁc targets.
Clinical Trial Registration-—URL: http://clinicaltrials.gov/. Unique identiﬁer: NCT00115934. (J Am Heart Assoc. 2014;3:
e000079 doi: 10.1161/JAHA.114.000079)
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I
nfants with hypoplastic left heart syndrome (HLHS) and
related single morphological right ventricular (RV) anom-
alies most commonly undergo the Norwood procedure before
1 week of age and a superior cavopulmonary connection
(stage II) at 4 to 6 months of age. These complex surgeries
impose a signiﬁcant metabolic stress on the infants, many of
who are already underweight at the time of their operation.
1–4
Growth failure has received considerable attention as a major
and potentially modiﬁable risk factor for increased morbidity,
prolonged hospitalization, and impaired neurodevelop-
ment.
3,5–7 Inferences regarding growth in this population
have been handicapped by inclusion of a variety of single
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ORIGINAL RESEARCHventricle morphologies, single center approaches, cross-
sectional study design, failure to standardize measurements,
and small sample sizes with limited power for multivariable
analysis.
8–11
The National Heart, Lung, and Blood Institute-sponsored
Pediatric Heart Network Single Ventricle Reconstruction (SVR)
Trial collected data prospectively on the largest cohort to date
of subjects with HLHS and other single RV anomalies
undergoing the Norwood procedure and randomized to either
a modiﬁed Blalock-Taussig shunt (MBTS) or right ventricle-to-
pulmonary artery shunt (RVPAS).
12 Consenting survivors from
this trial were enrolled for longitudinal follow-up in the SVR
Extension Study. This well-characterized cohort from a broad
sample of North American centers provided a unique oppor-
tunity to evaluate early growth and to identify potential risk
factors for poor growth. The goals of the present analysis
were to describe growth patterns during the ﬁrst 3 years of
life and to explore patient characteristics, perioperative
factors, shunt type, and other therapies that are associated
with growth in the SVR cohort.
Methods
Subjects
The design and main results of the SVR trial have been
reported previously.
12–14 Brieﬂy, neonates with HLHS or a
related single morphological RV anomaly and a planned
Norwood procedure were eligible for inclusion in the trial.
Those with a major congenital or acquired extracardiac
abnormality that could independently inﬂuence transplant-
free survival were excluded. Subjects undergoing a Norwood
procedure were randomized to either a MBTS or RVPAS.
Sociodemographic and clinical characteristics, medical and
surgical variables, unanticipated procedures, complications,
outcome data, and core laboratory analysis of echocardio-
graphic images were collected on subjects from birth to
14 months of age (Table 1). Consenting survivors of the SVR
trial were subsequently enrolled in the SVR Extension Study
with annual data collection from review of the medical record.
The study protocols were approved by each center’s institu-
tional review board or research ethics board and written
consent was obtained from a parent or guardian.
Study Design and Measurements
We analyzed changes in weight and length/height over time
to investigate growth patterns and assessed predictors of
these patterns using all available data on subjects from birth
through age 3 years. Because the factors contributing to
impaired weight gain may change over time (often as the
result of surgical or procedural alterations in physiology), the
3-year clinical course was divided into 4 clinically relevant
periods: (1) birth to Norwood discharge, (2) Norwood
discharge to stage II procedure (interstage), (3) stage II
procedure to 14 months, and (4) 14 months to 3 years of
age. Subjects who were premature (<37 weeks gestation,
n=64) did not have a Norwood procedure (n=5), or whose
parent/guardian withdrew consent in week 1 (n=1) were
excluded from this analysis. Subjects who subsequently
underwent heart transplantation or biventricular repair
(n=23) had growth data included only up to the transplant
or biventricular repair. Subjects who underwent the stage II
procedure without being discharged after the Norwood
procedure (n=22) were excluded from the analysis of the
ﬁrst 2 time periods. The shunt type in place when the subject
left the operating room following the Norwood procedure was
used for the analysis of the effect of shunt type on growth.
Medical and surgical data were collected from the neonatal
hospitalization, stage II hospitalization, and study visits up to
and including age 3 years. If the stage III procedure occurred
by 3 years of age, any surgeries and catheter interventions
occurring during that hospitalization were also included in the
predictor variables describing the number of procedures.
Covariates considered as potential correlates of growth in the
analysis are listed in Table 1.
Growth Assessment
All growth measurements were converted to age-adjusted z
scores in standard deviations (SD) based on World Health
Organization (WHO) standards.
15 The primary outcome was
the change in weight-for-age z score (WAZ) for each of the
designated time intervals. While a WAZ <2 is a traditional
screening criterion for growth failure in healthy individuals,
prior studies have demonstrated that simple cross-sectional
assessment using a single threshold is relatively insensi-
tive.
16 To better assess the severity of impaired weight gain,
we determined the proportion with WAZ <1, which
identiﬁes a potentially at-risk population and also offers
more statistical power, in addition to the more traditional
abnormal classiﬁcation of WAZ <2. Weights were obtained
at study visits, typically with infants weighed in a diaper and
older children in light clothing and barefoot. Because the
methodology for measuring height/length was not standard-
ized for the SVR Trial and given the challenges inherent in
obtaining length in infants,
17 we limited the analyses of
change in height/length z scores (LAZ) to the time from birth
to age 3 years. Changes seen over this longer time interval
are more likely due to somatic growth rather than inaccu-
racies in measurement.
18 For this analysis, pre-Norwood
length was deﬁned as the LAZ at birth and barefoot height
using a stadiometer at the 3-year study visit was deﬁned as
LAZ at 3 years.
DOI: 10.1161/JAHA.114.000079 Journal of the American Heart Association 2
Growth Patterns in Hypoplastic Left Heart Syndrome Burch et al
O
R
I
G
I
N
A
L
R
E
S
E
A
R
C
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Predicting Change in Weight-for-Age z Score for the
Designated Time Periods
Between birth and Norwood discharge:
General
Center
Socioeconomic Status (SES) and Hollingshead scores
Percentage of residents below federal poverty level
Medical insurance
Gender
Race/ethnicity
Anatomy subtype
Aortic atresia
Obstructed pulmonary return
Gestational age
Birth weight
Birth weight <2500 g
Multiple birth
Ever diagnosed with an identifiable genetic syndrome
Ever diagnosed with any genetic abnormalities
Pre-Norwood
Number of interventional catheterizations
Number/types of cardiac surgeries
Number/types of non-cardiac surgeries
Number of surgeries
Cardiopulmonary bypass time
Number of complications
Enteral feedings before Norwood
During Norwood hospitalization
Number/types of procedures performed concurrently
Number of interventional catheterizations
Number/types of cardiac surgeries
Number of non-cardiac surgeries
Number of complications
Length of hospital stay
Ventilator duration
Total bypass support time
Cross-clamp time
Regional perfusion time
Circulatory arrest time
Extracorporeal membrane oxygenation during Norwood
procedure or hospitalization
At Norwood discharge
Oxygen saturation
Continued
Table 1. Continued
Feeding method
Feeding type
Caloric density
Weight monitoring program
Oxygen monitoring program
Number of serious adverse events through discharge
Baseline echocardiogram
Right ventricular area change
Right ventricular ejection fraction
Neoaortic valve regurgitation
Tricuspid valve regurgitation
Between Norwood discharge and pre-stage II:
All of the above plus:
Post Norwood echocardiogram
Right ventricular area change
Right ventricular ejection fraction
Neoaortic valve regurgitation
Tricuspid valve regurgitation
Pre-stage II echocardiogram
Right ventricular area change
Right ventricular ejection fraction
Neoaortic valve regurgitation
Tricuspid valve regurgitation
Before stage II procedure
Feeding method
End diastolic ventricular pressure
Capillary wedge pressure
Number of interventional catheterizations
Number/types of cardiac surgeries
Number of non-cardiac surgeries
Cardiopulmonary bypass time
Number of complications
Number of serious adverse events
Between pre-stage II and 14 months:
All of the above plus:
During stage II hospitalization
Number/types of procedures performed concurrently
Reason for procedure (elective/nonelective)
Age at time of procedure
Total support time
Number of interventional catheterizations
Number/types of cardiac surgeries
Continued
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Because of the high mortality over time in this population, the
analysis of weight was performed at each time interval. Given
that the analysis examined only survivors of each staged
surgery, understanding the factors that predicted weight gain
in each phase was most clinically relevant. Descriptive
statistics include meanSD for continuous variables and
frequency with percentage for categorical variables. Each
mean was based on data available at the respective time point
(Figure 1A through 1C). Simple linear regression was used to
obtain initial estimates of association of each candidate
predictor with change in WAZ and LAZ at each time interval.
Nonlinear relationships with continuous outcomes were
assessed by categorizing continuous variables into groups
based on quartiles; in addition, relationships between the
natural logarithm of predictors with skewed distributions (for
example, length of hospital stay) and the outcomes were
explored. All variables with unadjusted P<0.20 were used as
candidate predictors for multivariable modeling. For variables
with >5% missing data (for example, socioeconomic predic-
tors and the use of weight and/or oxygen monitoring
programs), mean imputation was performed prior to con-
ducting multivariable modeling. Stepwise linear regression
was employed to develop multivariable models, in conjunc-
tion with bootstrapping (1000 samples) to obtain reliability
estimates for each of the predictors. The criteria to enter
and remain in the model were P<0.15 and P<0.05,
respectively. Separate models were constructed adjusting,
and not adjusting, for center. All terms in the ﬁnal
multivariable models have a reliability >50% and P<0.05.
Only the models where center was not allowed as a
potential covariate in the model are included in the Tables 3
through 8. Center effects are described in the text. All
analyses were conducted using SAS version 9.3 (Statistical
Analysis System, SAS Institute, Inc) and SAS macros for
bootstrapping estimates of reliability.
Results
Study Cohort
Flow charts of the subjects included in the analysis of growth
parameters at each time period are shown in Figures 1A
through 1C. At birth, compared with a mean of 0 for the
normative population, the mean for both WAZ and LAZ
(Figure 2) was lower for subjects in the SVR cohort (P<0.001
for WAZ, P=0.05 for LAZ). Birth weight was >1 SD below
expected population mean (WAZ <1) in 24% and >2S D
below (WAZ <2) in 6%. LAZ at birth was <1 in 23% and
<2i n1 0 % .
Table 1. Continued
Number of non-cardiac surgeries
Number of complications
Length of hospital stay
Ventilator duration
Regional perfusion time
Circulatory arrest time
Extracorporeal membrane oxygenation during stage II procedure or
hospitalization
Oxygen saturation at discharge
Any cardiopulmonary resuscitation used after stage
II procedure
From post-stage II to 14 months
Number of interventional catheterizations
Number/types of cardiac surgeries (through 12 months)
Number of non-cardiac surgeries (through 12 months)
Cardiopulmonary bypass time
Number of complications
Number of serious adverse events
14 month echocardiogram
Right ventricular area change
Right ventricular ejection fraction
Neoaortic valve regurgitation
Tricuspid valve regurgitation
Between 14 months and 3 years and for change in weight-for-age
z score between birth and 3 years, and change in height/length-
for-age z score between birth and 3 years:
All of the above plus:
From 12 or 14 months to 3 years
Number of interventional catheterizations
Number/types of cardiac surgeries
Number of complications
Number of medications
Feeding method 13 to 24 months
Feeding method 25 to 36 months
Speech/language/occupational therapy 13 to 24 months
Speech/language/occupational therapy 25 to 36 months
Feeding issues 13 to 24 months
Feeding issues 25 to 36 months
Therapy for feeding issues 13 to 24 months
Therapy for feeding issues 25 to 36 months
Solid foods 13 to 24 months
Solid foods 25 to 36 months
Special foods 13 to 24 months
Special foods 25 to 36 months
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Over the entire study period, the greatest drop in WAZ in this
cohort was seen between birth and Norwood discharge with
continued gradual decline through the interstage period to the
stage II procedure, followed by the period of greatest gain
occurring between stage II and 14 months (Table 2). At age
3 years, both mean WAZ and LAZ (Figure 2) were lower than
the mean of the normative population (P<0.001); furthermore,
WAZ was <1 in 30% and <2 in 6% and LAZ was <1i n
58% and <2 in 18% of subjects (Figure 1A).
We sought correlates of impaired growth and found that
a higher birth weight was independently associated with a
greater drop in both WAZ and LAZ by age 3 years. Longer
Norwood hospitalization, a larger number of concurrent
procedures at stage II, and moderate to severe tricuspid
regurgitation at 14 months were independently associated
with a greater decline in WAZ (Table 3) during this time
period. The correlates of a decline in height were more
difﬁcult to interpret (Table 4). Cross clamp and total
cardiopulmonary support times for the Norwood operation
and total number of interventional procedures from
14 months to 3 years were independently associated with
LAZ but the relationships were not linear. Although
counterintuitive and nonlinear, lower right ventricular ejec-
tion fraction at the pre-stage II echo was also associated
with a greater increase in LAZ at age 3 years. The type of
shunt in place when leaving the operating room had no
association with change in either WAZ or LAZ from birth to
age 3 years.
AB C
Figure 1. A, Flow diagram showing the study sample used for the growth analysis from birth to age 3 years (without intermediate time points).
B, Flow diagram showing the study sample used for the growth analysis for birth weight to each of the ﬁrst 2 time periods: (1) Birth to Norwood
discharge; (2) Norwood discharge to pre-stage II. C, Flow diagram showing the study sample used for the growth analysis for pre-stage II and the
last 2 time periods: (1) Pre-stage II to age 14 months, (2) Age 14 months to age 3 years. SVR indicates Single Ventricle Reconstruction.
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The most dramatic drop in WAZ occurred from birth to
Norwood discharge, with 91% of subjects having ≥0.5 SD drop
in mean WAZ. WAZ was <1 in 72% and <2 in 37% of
subjects at the time of discharge. The mean change in WAZ
was 1.400.80 (95% CI 1.48 to 1.33, P<0.001, Table 2)
and did not differ by shunt type. Male gender, higher birth
weight, pre-Norwood enteral feeding, mechanical ventilation
>5 days, and prolonged Norwood hospitalization were inde-
pendent predictors of a decline in WAZ (Table 5). Total
cardiopulmonary support time was also independently asso-
ciated with a fall in WAZ and, although the relationship was
nonlinear, support times >170 minutes had the largest drop
in WAZ (Figure 1B).
Norwood Discharge to Stage II Procedure
(Interstage)
The interstage period was characterized by a much smaller fall
in WAZ than was observed during the birth to Norwood
discharge interval. As a result, WAZ was <1i n7 2 %a t
Norwood discharge and 72% at stage II. Compared with the
37% with WAZ <2 at Norwood discharge, 39% of subjects
had WAZ <2 at stage II. In contrast to all other time periods,
shunt type was associated with change in WAZ during the
interstage period (P=0.002, Table 2). WAZ did not change in
subjects with RVPAS (0.081.09, 95% CI 0.08 to 0.23,
P=0.32) while there was a decline in WAZ in those with MBTS
(0.291.06, 95% CI 0.46 to 0.12, P=0.001). The
relationship between shunt type and change in WAZ remained
statistically signiﬁcant when adjustment was made for center
(Figure 1B).
Multivariable analysis for the interstage period demon-
strated that higher birth weight, lower socioeconomic status
score, absence of pre-Norwood enteral feeding, increased
number of interstage complications, and method of feeding
pre-stage II were independently associated with a mean
interstage decrease in WAZ (Table 6). Infants receiving
gastrostomy or gastrojejunostomy tube feedings in the
interstage period had the greatest rise in WAZ.
Figure 2. Graph demonstrating weight-for-age z score over all
time periods and length-for-age z score at birth and age 3 years.
Each mean is based on all data available at the respective time
point, ranging from N=485 at birth to N=268 at age 3 years. The
error bars represent one standard deviation. LAZ indicates
length/height-for-age z score; WAZ, weight-for-age z score.
Table 2. Changes in Weight-for-Age z Scores for Each Time Period
Time Period Time Between Measurements
Change in Weight-for-Age z Score
MeanStandard Deviation (n)
P Value Comparing
Shunts
† All Subjects* MBTS RVPAS
Birth to Norwood discharge (days) 32.526.4 (424) 1.400.80
(424)
1.440.84
(210)
1.360.76
(214)
0.32
Norwood discharge to pre-stage II (months) 3.71.6 (348) 0.081.09
(348)
0.291.06
(153)
0.081.09
(195)
0.002
Pre-stage II to 14 (months) 9.53.2 (291) 1.000.97
(291)
1.120.92
(129)
0.911.00
(162)
0.06
Age 14 months to 3 years (months) 20.14.0 (268) 0.200.87
(268)
0.270.82
(123)
0.130.91
(145)
0.20
Birth to 3 years (years) 2.80.2 (310) 0.251.28
(310)
0.361.27
(144)
0.161.29
(166)
0.18
MBTS indicates modiﬁed Blalock-Taussig shunt; RVPAS, right ventricle-to-pulmonary artery shunt.
*Each mean was based on data available at the respective time point (Figures 1A through 1C).
†The P-value used to compare shunts was derived from a two-sample t test.
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Stage II to 14 months was characterized by catch-up growth
with 87% of subjects having a change in WAZ >0 (mean
change in WAZ of 1.000.97; 95% CI 0.89 to 1.12; P<0.001,
Table 2). WAZ was <1 in 38% and <2 in 12% of subjects
and only 5% had a drop in WAZ of ≥0.5. Older age at stage II
was associated with a greater drop in WAZ (Table 7). A
greater number of complications between Norwood discharge
and the stage II procedure were associated with a more
positive change in WAZ in this period. The length of stay at the
Norwood hospitalization and the Hollingshead Four Factor
Index of Socioeconomic Status had an independent but
nonlinear association with change in WAZ. Center was not
signiﬁcantly associated with growth in univariate analysis for
this period and therefore was not included in the multivariable
model (Figure 1C).
Age 14 Months to 3 Years
Although mean WAZ improved in this interval (0.200.87,
95% CI 0.09 to 0.30, P<0.001, Table 2), the increase was less
Table 3. Main Effects Multivariable Model for Change in Weight-for-Age z Score From Birth to 3 Years (n=310, Adjusted R
2=0.41)
Variable Estimate Standard Error P Value Reliability (%)
Birth weight, kg 1.654 0.116 <0.001 98
Tricuspid valve regurgitation at 14 month echo 0.01 70
≥Moderate 0.421 0.148
<Moderate Reference
Number of concurrent procedures at stage II procedure 0.151 0.065 0.021 59
Length of stay for Norwood (ln days) 0.261 0.091 0.005 54
Table 4. Main Effects Multivariable Model for Change in Length-for-Age z Score From Birth to 3 Years (n=294, Adjusted R
2=0.27)
Variable Estimate Standard Error P Value Reliability (%)
Birth weight, kg 1.478 0.18 <0.001 84
Total support time (Norwood) <0.001 68
≤107 minutes 0.819 0.328
108 to 139 minutes 0.273 0.309
140 to 170 minutes 0.107 0.283
>170 minutes Reference
Total cross clamp time (Norwood) 0.002 65
≤40 minutes 0.431 0.330
41 to 53 minutes 0.489 0.305
54 to 67 minutes 0.249 0.302
>67 minutes Reference
Number of interventional cardiac procedures from 14 months to 3 years 0.001 61
0 Reference
1 0.023 0.231
2 1.793 0.527
3+ 1.128 0.547
Right ventricular ejection fraction at pre-stage II echo 0.007 55
≤38.9% 0.207 0.291
39.0% to 43.6% 0.011 0.291
43.7% to 49.2% 0.360 0.285
>49.2% Reference
Unknown/missing 0.868 0.274
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stage II to 14 month period (Figure 2). The most counterin-
tuitive independent correlate of an increase in WAZ during this
time was the presence of pulmonary venous obstruction but
this may be an artifact related to the small number with
this pathology (N=5). Feeding method prior to stage II was
associated with mean change in WAZ and nasojejunal/
nasogastric feeding before stage II predicted the largest
increase in WAZ (Figure 1C; Table 8).
Discussion
The SVR Trial and SVR Extension Study have collected data
on the largest multicenter cohort of subjects with HLHS and
related single RV anomalies to date, allowing us to perform a
longitudinal assessment of both linear growth and weight
gain from birth to age 3 years. Even at birth, mean weight
and length of the SVR cohort were lower than the general
population. The most dramatic decline in WAZ occurred
between birth and Norwood discharge, with a relative
plateau during the interstage period. The greatest increase
in WAZ occurred after the stage II procedure, likely
secondary to ventricular volume unloading, as suggested
by other investigators.
8 Although growth improved after
stage II, both the mean WAZ and LAZ of the SVR cohort
remained below the mean of the normal population at age
3 years.
Predictors of change in WAZ varied with the time period
being analyzed and no consistent practice improved growth
from birth to age 3 years. This was not unexpected given the
changes in surgery and physiology during each interval. In
addition, interpretation of the models for prediction of change
in WAZ was made more difﬁcult by the fact that some time
periods differed in length among subjects since the timing of
Norwood discharge and the timing of the stage II procedure
were inconsistent. Although it is possible to speculate about
some of the observed associations, we preferred to avoid this
in the absence of supportive data. However, some data are
available to support several conclusions regarding predictors
of growth in HLHS patients undergoing single ventricle
palliation. The model for change in weight from birth to
Table 5. Main Effects Multivariable Model for Change in Weight-for-Age z Score From Birth to Norwood Discharge (n=417,
Adjusted R
2=0.33)
Variable Estimate Standard Error P Value Reliability (%)
Gender <0.001 96
Female 0.302 0.068
Male Reference
Birth weight, kg 0.340 0.067 <0.001 73
Length of hospital stay for Norwood procedure <0.001 72
≤16 days 0.846 0.118
17 to 24 days 0.474 0.114
25 to 40 days 0.160 0.105
>40 days Reference
Days on ventilator after Norwood procedure 0.04 72
≤5 days or less 0.209 0.118
6 to 7 days 0.024 0.119
8 to 12 days 0.017 0.117
>12 days Reference
Total bypass support time during Norwood procedure 0.03 68
≤107 minutes 0.014 0.096
108 to 139 minutes 0.057 0.096
140 to 170 minutes 0.251 0.097
>170 minutes Reference
Pre-Norwood enteral feeding
No 0.276 0.108 0.01 53
Yes Reference
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H3 years is particularly useful because it does not depend on
the timing of either procedure or the length of stay for the
Norwood hospitalization. In this model, longer total length of
stay for the Norwood operation, a greater number of
concurrent procedures at stage II, and moderate to severe
tricuspid regurgitation at 14 months were associated with
poor weight gain. These ﬁndings support the idea that
imperfect results from initial palliation contribute to poor long-
term weight gain. While it may seem counterintuitive that
patients who are larger at birth (and would be expected to
Table 6. Main Effects Multivariable Model for Interstage Change in Weight-for-Age z Score From Norwood Discharge to Pre-Stage
II (n=345, Adjusted R
2=0.21)
Variable Estimate Standard Error P Value Reliability (%)
Birth weight, kg 0.716 0.111 <0.001 78
SES score* (per unit increase) 0.035 0.011 0.001 74
Pre-Norwood enteral feeding <0.001 72
No 0.701 0.176
Yes Reference
Number of complications from Norwood discharge to pre-stage II 0.105 0.036 0.004 70
Shunt (non-intention to treat) 0.009 70
MBTS 0.282 0.107
RVPAS Reference
Feeding method pre-stage II <0.001 59
G/GJ tube 0.665 0.175
NJ/NG tube 0.028 0.239
Combination 0.104 0.141
Other 0.747 0.355
Oral Reference
G/GJ indicates gastric/gastojejunal; MBTS, modiﬁed Blalock Taussig shunt; NJ/NG, nasogastric/nasojejunal; RVPAS, right ventricular to pulmonary artery shunt.
*SES score was assigned using a US census-based score derived from 6 measures related to income, housing, and occupation-related features of the subject’s census block tract at the
time of randomization.
Table 7. Main Effects Multivariable Model for Change in Weight-for-Age z Score From Pre-Stage II and 14 Months (n=290,
Adjusted R
2=0.09)
Variable Estimate Standard Error P Value Reliability (%)
Norwood length of stay 0.02 60
≤16 days 0.352 0.165
17 to 24 days 0.371 0.153
25 to 40 days 0.476 0.157
>40 days Reference
Number of complications between Norwood discharge and stage II procedure 0.119 0.04 0.003 59
Ln age at stage II procedure, (months) 0.507 0.175 0.004 58
Hollingshead category
3.0 to 26.0 0.571 0.256 0.03 53
27.0 to 40.0 0.346 0.259
41.0 to 54.9 0.695 0.253
55.0 to 66.0 0.522 0.26
Missing Reference
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Hhave better outcomes) actually have poorer weight gain, this
ﬁnding has been reported by other investigators.
8 It most
likely reﬂects a regression to the mean where those with
lower birth weights simply have more opportunity to catch up
and therefore a greater improvement in WAZ.
19,20
The interstage model was largely consistent with what we
expected, including less weight gain in patients with higher
birth weight and more complications. Weight improved in
patients with higher socioeconomic status. Importantly, the
type of systemic-to-pulmonary-artery shunt affected weight
gain only during the interstage interval, when subjects with
MBTS had poorer weight gain than those with RVPAS. This
ﬁnding may be explained by the higher energy expenditure
associated with MBTS physiology.
21–23 Mortality was also
higher in the group with the MBTS during the interstage.
12
Ultimately, shunt type did not have long-term effects on
weight as the MBTS subjects who survived started to gain
weight after the volume unloading of the stage II procedure.
The variability in timing of stage II measurements and
inclusion of subjects who were not discharged after the
Norwood confound the model for the pre-stage II to 14-month
time period. Despite this, it appears that on average even the
sickest patients with the most complications and those with
unfavorable anatomy (obstructed pulmonary veins) gained
weight after stage II, if they survived.
The greater percentage of subjects who are short
compared with those underweight at age 3 years cannot
be explained by caloric intake alone. Typically, weight is
more affected than height by inadequate caloric intake.
23
However, at age 3 years, 3 times as many children were
short as were underweight (>2 SD below normal). The
recovery of weight without recovery of height should be
viewed with caution as it may represent an excessive
increase in adipose rather than an accumulation of lean body
mass.
24,25 Cross-sectional studies of stage II and Fontan
survivors reported both a lower LAZ and a positive corre-
lation between lower LAZ and developmental problems.
8,26 It
is unclear if this interaction is a direct relationship or the
result of an undiagnosed genetic defect. Genetic syndrome
was not associated with linear growth or weight gain in this
analysis but the SVR Trial relied on expert physical
examination, rather than contemporary genomic
technologies, so the ability to diagnose syndromes that are
not phenotypically apparent was limited.
27 As the knowledge
gap narrows with increasing investigations into the genetic,
epigenetic, and environmental basis for congenital heart
disease, we may better understand the variations in
phenotypes and difﬁculty in impacting both linear growth
and weight gain in children with HLHS and other single RV
anomalies.
28–31 Future studies evaluating abnormal body
composition may be informative and promote consideration
of therapies commonly used in other severe catabolic or
genetically based growth impaired states.
Limitations
Our study should be interpreted in light of some limitations.
First, it is important to note that the anthropometric data
presented in this report are conditional on transplant-free
survival to each respective time point, using all available data
to maximize precision of our estimates. As a result, qualitative
comparisons of the change in WAZ amongst the time
intervals, while of clinical interest, are based on cohorts of
decreasing size and subject to survivor bias. Second,
genotyping was not used to deﬁne genetic syndromes in
the SVR Trial. Children with potentially pathogenic copy
number variants or other genetic abnormalities often do not
have obvious clinical ﬁndings so are not diagnosed with a
syndrome,
27 potentially accounting for the failure to ﬁnd an
association between genetic syndrome and poor linear growth
Table 8. Main Effects Multivariable Model for Change in Weight-for-Age z Score From 14 Months to 3 Years (n=268, Adjusted
R
2=0.06)
Variable Estimate Standard Error P Value Reliability (%)
Feeding method before stage II procedure 0.006 77
1. G/GJ tube 0.153 0.171
2. NJ/NG tube 0.597 0.216
3. Combination 0.148 0.131
4. Other 1.622 0.85
5. Oral Reference
Obstructed pulmonary venous return 0.008 54
Yes 1.020 0.383
No Reference
G/GJ indicates gastric/gastojejunal; NJ/NG, nasogastric/nasojejunal.
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Hor weight gain in this study. Third, because the WHO
normative data do not allow adjustment for gestational age
at birth, we attempted to minimize the effect of differences in
gestational age by restricting our analysis to term infants.
Finally, detailed data regarding feeding practices and calories
were not collected in the SVR Trial, limiting our inferences
about their effect on weight and length.
Conclusions
Early patterns of weight gain in children with HLHS and other
single RV anomalies vary over time. Predictors of poor
weight gain also vary among time intervals and are difﬁcult
to interpret. Survivors of the Norwood procedure, including
those with complicated courses and unfavorable anatomy,
demonstrate catch-up weight gain following volume-unload-
ing surgery but both WAZ and LAZ remain below average at
age 3 years. Since length was affected more than weight at
age 3 years, it is unlikely that addressing caloric intake alone
will address growth impairment. Further investigation into
genetic and epigenetic causes for alterations in body
composition may suggest treatments to be tested in future
clinical trials.
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